Similar Posts
Price Transparency Thoughts from a Thought Leader (And Former Student)
ByadminHere is a great piece on my former student, Jessica Harris, who now works in health care price transparency at Aetna. She visited my class this summer, and here are some of the things she taught them: The evolution of transparency in the industry: “2013 and 2014 have been really important years for transparency and…
Peer Comparison Can Reduce Antibiotic Prescribing
ByadminVery interesting article in the Lancet recently, from the nudge unit in the United Kingdom. They give physicians feedback on how much they prescribed antibiotics compared to their peers, and found that such feedback reduced antibiotic prescriptions. I hope to see more of this work!
Best Email of the Week
ByadminI got an unusual email message a little while ago. It was from someone I had never met before, and it wasn’t obvious to me, at first, why this person was contacting me. The email began like this: “I am an engineer and I work in a company of public passenger transport in Buenos Aires….
Does the Thought of Money Make Us Dishonest?
ByadminHere is a game you can’t lose. You flip a fair coin ten times and every time it comes up heads, you get $20. Better yet, I won’t even watch you flip the coin, but instead will trust whatever you tell me about the number of times the coin comes up heads versus tails. Would…
The Key to Winning a Pulitzer? Don't Take Time To Think!
ByadminBret Stephens won a Pulitzer Prize for his foreign affairs column in the Wall Street Journal op-ed page. Only in his early 40s, Stephens can already boast of an enviable number of accomplishments. He has already been Editor-in-Chief of the Jerusalem Post. And he is now Deputy Editor at the Wall Street Journal, one of…
Copay Assistance Controversy Continues
ByadminMy article with Peter Bach of Memorial Sloan Kettering continues to generate debate. The two of us argues that copay assistance programs from pharmaceutical companies help specific patients in the short run, but make it easier for drug companies to demand high prices for their products. Here is one take on the topic, spurred on…

